Polaris Partners

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Delphia Therapeutics operates and manages a laboratory that develops treatments for cancer cells. It studies cancer-driving pathways and their effect on creating cancer medicines. Delphia Therapeutics is based in Boston, USA.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Contact Networks is a Boston-based company that specializes in Enterprise Relationship Management (ERM) software solutions designed to assist professional services firms in maximizing their relationship networks to drive new business opportunities. The company's flagship product, ContactNet, is an automated search application that quickly identifies employees with the strongest relationships to potential clients or prospects. This service helps organizations uncover existing professional connections, allowing for more effective client engagement. By providing an easy-to-use platform that integrates with existing IT and CRM systems, Contact Networks enhances the ability of firms to leverage their internal networks for business development. The company was acquired by Thomson Reuters in 2007.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on developing solutions to mitigate healthcare cyber incidents related to patient data theft, specifically targeting the needs of chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patients’ protected health information (PHI). By adopting a proactive risk management approach, the platform aims to improve patient care, clinician satisfaction, regulatory compliance, and innovation rates, ultimately helping healthcare organizations assess and reduce the risks associated with data breaches.

Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

76Bio is a biotechnology company based in New York that focuses on developing innovative therapies for patients with life-threatening diseases. Founded in 2020, the company specializes in targeted protein degraders, a class of therapeutics designed to selectively degrade unneeded proteins in the body. By leveraging advanced technology, 76Bio aims to create transformational treatments that address critical medical needs, offering hope for improved outcomes in patients suffering from serious health conditions.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

OM1, Inc. is a digital health company that specializes in developing a platform for healthcare organizations to measure and forecast patient outcomes. The platform is designed to assist hospitals, health systems, and other healthcare providers in meeting various patient reported and clinical outcomes requirements for value-based care programs. By leveraging advanced predictive and prescriptive analytics, OM1 aims to mitigate risks, lower costs, and enhance the understanding of treatment outcomes across the care continuum. The company's technology gathers and synthesizes clinical data to provide AI-driven insights, enabling healthcare organizations to analyze and utilize outcomes data effectively. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

Wellthy, Inc. is a concierge service based in New York that assists individuals and families in managing care for chronically ill, aging, or disabled loved ones. Established in 2014, the company connects families with dedicated Care Coordinators who help navigate complex care situations, including aging-related issues such as dementia, diabetes, and cancer, as well as childcare and special needs. Wellthy's platform enables families to efficiently organize appointments, manage tasks, store essential documents, and maintain communication, alleviating the logistical burdens associated with caregiving. The service aims to provide relief to families by coordinating care and addressing related medical, legal, financial, and housing needs.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that operates web-based platforms tailored to patients with chronic conditions. Founded in 2016, the company offers a range of specialized healthcare brands, including Keeps for men’s hair loss, Cove for migraines, Picnic for allergies, Facet for skin conditions, and NURX for sexual health. Each brand is designed to provide personalized treatments and care, addressing the unique needs of its community. By focusing on specific ongoing conditions, Thirty Madison seeks to empower individuals through accessible and effective healthcare solutions, facilitating exceptional outcomes for patients over a lifetime of care.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on developing solutions to mitigate healthcare cyber incidents related to patient data theft, specifically targeting the needs of chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patients’ protected health information (PHI). By adopting a proactive risk management approach, the platform aims to improve patient care, clinician satisfaction, regulatory compliance, and innovation rates, ultimately helping healthcare organizations assess and reduce the risks associated with data breaches.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Sonrai Security Inc. offers an enterprise identity and data governance platform designed for public cloud environments, including AWS, Azure, Google Cloud, and Kubernetes. The platform, known as Sonrai Dig, utilizes a sophisticated graph to identify and monitor the relationships between identities and data within an organization’s cloud infrastructure. It features a Governance Automation Engine that streamlines workflows, remediation, and prevention processes for cloud and security teams, thereby enhancing overall security. Sonrai Security serves various sectors, including education, healthcare, financial services, and telecommunications, providing solutions that address cloud security posture management, identity governance, and compliance needs. Founded in 2017 and headquartered in New York, the company also maintains offices in Canada, focusing on empowering organizations to mitigate data threats and improve operational efficiency in DevSecOps environments.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Neogene Therapeutics, Inc. is a biotechnology company based in New York, founded in 2018, that focuses on developing T cell therapies for cancer treatment. The company specializes in creating personalized engineered T cells that target neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. By leveraging advanced technologies, Neogene isolates T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies routinely collected from patients. This process utilizes high-sensitivity DNA sequencing and genetic screening to identify TCRs that can effectively recognize and attack cancer cells. Neogene's innovative approach aims to enhance the precision and efficacy of cancer therapies, offering improved treatment options for patients facing a broad spectrum of cancers.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that operates web-based platforms tailored to patients with chronic conditions. Founded in 2016, the company offers a range of specialized healthcare brands, including Keeps for men’s hair loss, Cove for migraines, Picnic for allergies, Facet for skin conditions, and NURX for sexual health. Each brand is designed to provide personalized treatments and care, addressing the unique needs of its community. By focusing on specific ongoing conditions, Thirty Madison seeks to empower individuals through accessible and effective healthcare solutions, facilitating exceptional outcomes for patients over a lifetime of care.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Amagma Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2019. The company focuses on the discovery and development of antibody therapeutics aimed at treating inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma targets overactive extracellular proteases that lead to tissue damage and contribute to widespread inflammatory responses. By addressing these mechanisms, the company aims to provide effective and safe therapeutic options for clinicians dealing with such conditions.

1366 Technologies is a manufacturer of silicon wafers used to deliver solar modules. The company's silicon wafers leverage existing billion-dollar cell and module investments, enabling businesses to get a long-term, differentiated product roadmap. It was founded in 2008 and is headquartered in Bedford, Massachusetts.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Caledonia Spirits operates a craft distillery firm created to support working landscapes and local agriculture. The distillery produces the Bar Hill Gin, Tom Cat Gin, and Barr Hill Vodka, all of which feature raw honey and other ingredients including grains sourced as locally and as organically as possible. The purpose of Caledonia Spirits is to add value to the work of the people of Vermont, including those growing grains, herbs, medicinal plants, and honey, and to support and encourage the organic production of plants and honey in Vermont and surrounding regions, and to provide employment and contribute to the health, spiritual, economic, and social well-being of the community, and honor the traditions of Vermont, Scotland, France, Quebec, and other agricultural communities that inspire its formulations. The Hardwick, Vermont-based distillery was founded in 2012 by Todd Hardie.

Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.

Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company specializes in soluble guanylate cyclase (sGC) pharmacology to realize the therapeutic potential of next-generation sGC stimulators. Its product pipeline includes Olinciguat, an oral sGC stimulator currently in Phase II trials for sickle cell disease; Praliciguat, also an oral sGC stimulator in Phase II for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, which is in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is engaged in the discovery of liver-targeted and lung-targeted sGC stimulators. Founded in 2018, the company is headquartered in Cambridge, Massachusetts.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Wellthy, Inc. is a concierge service based in New York that assists individuals and families in managing care for chronically ill, aging, or disabled loved ones. Established in 2014, the company connects families with dedicated Care Coordinators who help navigate complex care situations, including aging-related issues such as dementia, diabetes, and cancer, as well as childcare and special needs. Wellthy's platform enables families to efficiently organize appointments, manage tasks, store essential documents, and maintain communication, alleviating the logistical burdens associated with caregiving. The service aims to provide relief to families by coordinating care and addressing related medical, legal, financial, and housing needs.

Sonrai Security Inc. offers an enterprise identity and data governance platform designed for public cloud environments, including AWS, Azure, Google Cloud, and Kubernetes. The platform, known as Sonrai Dig, utilizes a sophisticated graph to identify and monitor the relationships between identities and data within an organization’s cloud infrastructure. It features a Governance Automation Engine that streamlines workflows, remediation, and prevention processes for cloud and security teams, thereby enhancing overall security. Sonrai Security serves various sectors, including education, healthcare, financial services, and telecommunications, providing solutions that address cloud security posture management, identity governance, and compliance needs. Founded in 2017 and headquartered in New York, the company also maintains offices in Canada, focusing on empowering organizations to mitigate data threats and improve operational efficiency in DevSecOps environments.

Drizly is an online marketplace specializing in the delivery of alcoholic beverages, including beer, wine, and spirits. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly operates in 235 markets, providing consumers of legal drinking age with a convenient and personalized shopping experience. The platform offers a diverse selection of products, allowing customers to order not only alcoholic drinks but also accompanying items like mixers and garnishes, all from the comfort of their homes. By partnering with local retailers, Drizly helps these businesses expand their reach and gain valuable market insights, ultimately aiding them in increasing sales and diversifying their offerings.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Twistlock Inc. specializes in providing comprehensive security solutions for containerized applications, enabling organizations to secure their DevOps environments. Founded in 2015 and based in Portland, Oregon, with additional offices in New York City and Tel-Aviv, Twistlock offers a robust platform that integrates seamlessly into continuous integration (CI) workflows. Its services include a vulnerability management system that identifies code vulnerabilities and configuration errors, as well as real-time threat protection and policy enforcement for applications in production. Trusted by a significant portion of the Fortune 100, Twistlock’s platform is designed for cloud-native technologies, such as Docker and Kubernetes, ensuring that security measures are embedded throughout the development lifecycle. As of July 2019, Twistlock operates as a subsidiary of Palo Alto Networks, further enhancing its capabilities in the cybersecurity landscape.

Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

OM1, Inc. is a digital health company that specializes in developing a platform for healthcare organizations to measure and forecast patient outcomes. The platform is designed to assist hospitals, health systems, and other healthcare providers in meeting various patient reported and clinical outcomes requirements for value-based care programs. By leveraging advanced predictive and prescriptive analytics, OM1 aims to mitigate risks, lower costs, and enhance the understanding of treatment outcomes across the care continuum. The company's technology gathers and synthesizes clinical data to provide AI-driven insights, enabling healthcare organizations to analyze and utilize outcomes data effectively. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Quentis Therapeutics, Inc. is a biotechnology company based in New York, founded in 2016. The company specializes in developing immunotherapies that target endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By addressing ER stress, Quentis aims to enhance the immune system's capacity to combat cancer, providing patients with innovative treatment options. Its therapeutic approach focuses on awakening anti-tumor immunity, thereby potentially improving outcomes for individuals facing various forms of cancer.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

Neuronetics, Inc. is a commercial stage medical technology company that specializes in developing non-invasive therapies for psychiatric disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company markets the NeuroStar Advanced Therapy System, which provides a non-invasive treatment for adults suffering from major depressive disorder. This system employs transcranial magnetic stimulation (TMS) to generate a pulsed, MRI-strength magnetic field that induces electrical currents aimed at stimulating specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team targeting psychiatrist customers, focusing on improving the quality of life for individuals with mental health challenges.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Twistlock Inc. specializes in providing comprehensive security solutions for containerized applications, enabling organizations to secure their DevOps environments. Founded in 2015 and based in Portland, Oregon, with additional offices in New York City and Tel-Aviv, Twistlock offers a robust platform that integrates seamlessly into continuous integration (CI) workflows. Its services include a vulnerability management system that identifies code vulnerabilities and configuration errors, as well as real-time threat protection and policy enforcement for applications in production. Trusted by a significant portion of the Fortune 100, Twistlock’s platform is designed for cloud-native technologies, such as Docker and Kubernetes, ensuring that security measures are embedded throughout the development lifecycle. As of July 2019, Twistlock operates as a subsidiary of Palo Alto Networks, further enhancing its capabilities in the cybersecurity landscape.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Qstream, Inc. is a software as a service company that offers a mobile sales acceleration platform designed to enhance job proficiency and drive behavioral change within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves various industries, including technology, financial services, and life sciences. The company specializes in micro-learning and analytics, aiming to improve the effectiveness of sales personnel through measurable outcomes. Qstream also has engineering facilities in Dublin, Ireland, and Hood River, Oregon, along with sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

B12 is a company that creates and operates a human-assisted artificial intelligence platform focused on simplifying the website design process. Founded in 2015 and based in New York, B12 provides an online platform called Orchestra that integrates with various third-party tools, including e-commerce and blogging services. This platform alerts experts to any quality issues in web designs and aims to deliver a comprehensive business solution. B12's services encompass website creation, search engine optimization, online scheduling, and payment processing, enabling businesses to establish an online presence efficiently. With a combination of advanced software and a network of creative professionals, B12 helps clients launch their services online within 30 days, facilitating effective client communication and relationship management.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Boxever Ltd. is a customer intelligence service provider specializing in the travel industry, founded in 2010 and headquartered in Dublin, Ireland, with an additional office in Boston. The company leverages data and artificial intelligence to help travel companies enhance customer relationships by integrating both online and offline customer data. Boxever's platform includes several key solutions: BOXEVER TX, which visualizes the customer journey; TX-CORE, a traveler experience management platform that anticipates customer needs; and TX-NOW, an offer management platform. The company collaborates with major brands, including Emirates and Ryanair, to deliver personalized customer experiences and optimize every interaction. Recognized for its innovative use of AI, Boxever has been acknowledged as a leading player in personalization within the industry.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, it is focused on discovering and developing innovative genome editing therapeutics to address a wide range of serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 technology, which employs a protein-RNA complex to target and modify specific DNA sequences for therapeutic purposes. Editas Medicine aims to translate its advanced genome editing technologies into human therapeutics that can provide precise and corrective molecular modifications to treat genetic disorders. With a strong foundation of patent filings and intellectual property, the company is positioned to advance its early findings into viable treatments for various diseases at the genetic level.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Established in 2011 and based in Waltham, Massachusetts, the company is engaged in creating pharmaceutical preparations aimed at diagnosing and treating oncological, tumor, and inflammatory diseases. XTuit Pharmaceuticals employs novel strategies to enhance cancer therapy by specifically addressing the tumor microenvironment. Its drug development pipeline includes innovative approaches that inhibit extracellular matrix synthesis and stabilize activated stromal cells, utilizing a clinical biomarker platform for effective treatment outcomes.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.